# Tirzepatide Dosage in the Research Literature — Escalation Schedules, Half-Life, and Pharmacokinetics

> Tirzepatide dosage data from the SURMOUNT and SURPASS trials: 2.5 mg starting dose through 15 mg maximum, once-weekly schedule, 5.4-day half-life, and subcutaneous pharmacokinetics.

## Tirzepatide dosage in clinical trials: what the research used

Across the SURPASS and SURMOUNT programs, all phase 3 trials used an identical starting dose and escalation schedule: 2.5 mg subcutaneous injection once weekly for the first 4 weeks, then 5 mg once weekly [2, 5]. From 5 mg, dose increases of 2.5 mg every 4 weeks were permitted to a maximum of 15 mg. The starting dose of 2.5 mg is a titration dose below the minimum therapeutic dose of 5 mg [14].

## Tirzepatide Half-Life and Pharmacokinetics

Population pharmacokinetic modeling from Schneck and Urva (2024) characterized tirzepatide's pharmacokinetics in 4,344 participants [24]:

- **Half-life:** approximately 5.4 days (range 4.9–5.8 days)
- **Subcutaneous bioavailability:** ~80%
- **Tmax:** 8–72 hours post-injection
- **Volume of distribution at steady state:** ~2.47 L in a 70 kg reference subject
- **Plasma protein binding:** ~99% (albumin-bound via the C20 fatty acid modification)
- **Accumulation ratio:** 1.7-fold at steady state
- **Time to steady state:** approximately 4 weeks of once-weekly dosing

The ~5.4-day half-life supports once-weekly dosing: plasma concentrations remain above the therapeutic threshold across the 7-day interval [24].

## How Long Does Tirzepatide Stay in Your System?

Half-life approximately 5 days (120 hours); full elimination takes approximately 4–5 half-lives (~25 days) [24]. After discontinuation, plasma concentrations fall below 10% of steady-state trough after approximately 4 weeks.

## Tirzepatide Onset of Action in Clinical Trials

Glycemic effects are measurable within the first week [2]. Meaningful weight loss was typically first measured at weeks 4–8; maximum efficacy was documented at week 72 in SURMOUNT-1 with no plateau at the highest dose [5].

## Escalation Schedule Documented in Phase 3 Trials

| Week Range | Dose |
|---|---|
| Weeks 1–4 | 2.5 mg once weekly |
| Weeks 5–8 | 5 mg once weekly |
| Weeks 9–12 | 7.5 mg once weekly |
| Weeks 13–16 | 10 mg once weekly |
| Weeks 17–20 | 12.5 mg once weekly |
| Week 21+ | 15 mg once weekly (maximum dose) |

## Storage and Administration in the Trial Record

Tirzepatide is stored refrigerated at 2–8°C; can be maintained at room temperature (up to 30°C) for up to 21 days. Sensitive to light; must not be frozen. Subcutaneous injection into the abdomen, upper arm, or thigh [14].

## References

[2] Rosenstock J, et al. SURPASS-1. Lancet. 2021;398(10295):143-155.
[5] Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387(3):205-216.
[6] Wadden TA, et al. SURMOUNT-3. Nature Medicine. 2023;29(11):2909-2918.
[7] Aronne LJ, et al. SURMOUNT-4. JAMA. 2024;331(1):38-48.
[9] Kaneko S. touchREVIEWS in Endocrinology. 2022;18(1):10-17.
[10] Urva S, et al. Diabetes Obes Metab. 2020;22:1886-1891.
[14] U.S. FDA. Tirzepatide Prescribing Information. 2024.
[22] Liu QK. Frontiers in Endocrinology. 2024;15:1431292.
[24] Schneck K, Urva S. CPT Pharmacometrics Syst Pharmacol. 2024;13:494-503.

---

The tirzepatide clinical record — mechanism, trials, and pharmacokinetics — read from primary sources, cited numerically, and held by no clinic and no vendor.